drugset / Trial / NCT01608542

A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects

NCT01608542

Phase 1 Completed 24 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelBasic science

Summary

This is a single and multiple dose study in healthy male and female (of non-child bearing potential) Japanese volunteers, to assess the blood and urine drug levels of Fostamatinib. Fostamatinib is being developed for the treatment of rheumatoid arthritis.

Timeline

Start
2012-06
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Fostamatinib Small molecule 100 mg Oral
Subject Fostamatinib Small molecule 200 mg Oral

Indications

No indication recorded.